June 25, 2012
‘Master molecule’ may improve stem cell heart attack treatment
Johns Hopkins researchers have discovered that a single protein molecule may hold the key to turning cardiac stem cells into blood vessels or muscle tissue, a finding that may lead to better ways to treat heart attack patients.
Human heart tissue does not heal well after a heart attack, instead forming debilitating scars. For reasons not completely understood, however, stem cells can assist in this repair process by turning into the cells that make up healthy heart tissue, including heart muscle and blood vessels. Recently, doctors elsewhere have reported promising early results in the use of cardiac stem cells to curb the formation of unhealthy scar tissue after a heart attack. But the discovery of a “master molecule” that guides the destiny of these stem cells could result in even-more-effective treatments for heart patients, the Johns Hopkins researchers say.
In a study published in the June 5 online edition of the journal Science Signaling, the team reported that tinkering with a protein molecule called p190RhoGAP shaped the development of cardiac stem cells, prodding them to become the building blocks for either blood vessels or heart muscle. The team members said that by altering levels of this protein, they were able to affect the future of these stem cells.
“In biology, finding a central regulator like this is like finding a pot of gold,” said Andre Levchenko, a biomedical engineering professor and member of the Johns Hopkins Institute for Cell Engineering, who supervised the research effort.
The lead author of the journal article, Kshitiz, a postdoctoral fellow who uses only his first name, said, “Our findings greatly enhance our understanding of stem cell biology and suggest innovative new ways to control the behavior of cardiac stem cells before and after they are transplanted into a patient. This discovery could significantly change the way stem cell therapy is administered in heart patients.”
Earlier this year, a medical team at Cedars-Sinai Medical Center in Los Angeles reported initial success in reducing scar tissue in heart attack patients after harvesting some of the patient’s own cardiac stem cells, growing more of these cells in a lab and transfusing them back into the patient.
Using the stem cells from the patient’s own heart prevented the rejection problems that often occur when tissue is transplanted from another person.
Levchenko’s team wanted to figure out, at the molecular level, what causes the stem cells to change into helpful heart tissue. If they could solve this mystery, the researchers hoped the cardiac stem cell technique used by the Los Angeles doctors could be altered to yield even better results.
During their research, the Johns Hopkins team members wondered whether changing the surface where the harvested stem cells grew would affect the cells’ development. The researchers were surprised to find that growing the cells on a surface whose rigidity resembled that of heart tissue caused the stem cells to grow faster and to form blood vessels. A cell population boom occurred far less often in the stem cells grown in the glass or plastic dishes typically used in biology labs. This result also suggested why formation of cardiac scar tissue, a structure with very different rigidity, can inhibit stem cells naturally residing there from regenerating the heart.
Looking further into this stem cell differentiation, the Johns Hopkins researchers found that the increased cell growth occurred when there was a decrease in the presence of the protein p190RhoGAP.
“It was the kind of master regulator of this process,” Levchenko said. “And an even bigger surprise was that if we directly forced this molecule to disappear, we no longer needed the special heart-matched surfaces. When the master regulator was missing, the stem cells started to form blood vessels, even on glass.”
A final surprise occurred when the team decided to increase the presence of p190RhoGAP, instead of making it disappear.
“The stem cells started to turn into cardiac muscle tissue, instead of blood vessels,” Levchenko said. “This told us that this amazing molecule was the master regulator not only of the blood vessel development, but that it also determined whether cardiac muscles and blood vessels would develop from the same cells, even though these types of tissue are quite different.”
But would these lab discoveries make a difference in the treatment of living beings? To find out, the researchers, working on the heart-matching surfaces they had designed, limited the production of p190RhoGAP within the heart cells. The cells that possessed less of this protein integrated more smoothly into an animal’s blood vessel networks in the aftermath of a heart attack. In addition, more of these transplanted heart cells survived, compared to what had occurred in earlier cell-growing procedures.
Kshitiz said that the special heartlike surface on which the cardiac stem cells were grown triggers regulation of the master molecule, which then steers the next steps.
“This single protein can control the cells’ shape, how fast they divide, how they become blood vessel cells and how they start to form a blood vessel network,” he said. “How it performed all of these myriad tasks that require hundreds of other proteins to act in a complex interplay was an interesting mystery to address, and one that rarely occurs in biology. It was like a molecular symphony being played in time, with each beat placed right at the moment before another melody has to start.”
Along with Levchenko and Kshitiz, the co-authors of the study were Eun Hyun Ahn and Deok-Ho Kim, both of the University of Washington and formerly of Johns Hopkins, and Johns Hopkins researchers Maimon E. Hubbi, John Downey, Junaid Afzal, Sergio Rey, Connie Chang, Arnab Kundu, Gregg L. Semenza, and Roselle M. Abraham.
Funding for the research was provided by the National Institutes of Health, the American Heart Association, the American Asthma Foundation and other sources.
The findings are protected in part by a provisional patent filed through the Johns Hopkins Technology Transfer Office.
Andre Levchenko’s lab:
Biomedical Engineering at Johns Hopkins:
Johns Hopkins Institute for Cell Engineering: